Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. by Seligmann, JF et al.
 1 
Investigating the poor outcomes of BRAF-mutant advanced colorectal 
cancer to develop practical treatment strategies 
 
Jenny F. Seligmann1, David Fisher2, Christopher G. Smith3, Susan D. 
Richman1, Faye Elliott,1 Sarah Brown4, Richard Adams3, Tim Maughan5, 
Philip Quirke1,Jeremy Cheadle3, Matthew Seymour1* and Gary Middleton6*. 
 
Corresponding Author 
 
Professor Gary Middleton 
Institute of Immunology and Immunotherapy, University of Birmingham and 
University Hospital Birmingham, UK 
Tel: 44 7789502237 
Email: G.Middleton@bham.ac.uk 
 
Affiliations 
 
1. Leeds Institute of Cancer and Pathology, University of Leeds, St. James’s 
University Hospital, Beckett St., Leeds, United Kingdom, LS9 7TF. 
2. Medical Research Council Clinical Trials Unit, University College London, 
London, London 
3. Institute of Medical Genetics, Institute of Cancer and Genetics, Cardiff 
University, Cardiff, United Kingdom  
4. Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK 
5. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, 
Oxford 
6. Institute of Immunology and Immunotherapy, University of Birmingham and 
University Hospital Birmingham, UK 
 2 
* MTS and GM are joint senior authors 
 
Key words 
Colorectal cancer; BRAF-mutant; chemotherapy; prognosis 
 
Word count: 3065 
  
 3 
Abstract 
Background: 
To improve strategies for the treatment of BRAF-mutant advanced colorectal 
cancer (aCRC) patients we examined individual data from patients treated 
with chemotherapy alone in three randomised trials to identify points on the 
treatment pathway where outcomes differ from BRAF wild-types. 
 
Patients and Methods: 
2530 aCRC patients were assessed from three randomised trials. End-points 
were progression free survival (PFS), response rate (RR), disease control rate 
(DCR), post-progression survival (P-PS) and overall survival (OS). 
Treatments included first-line oxaliplatin/fluorouracil (OxFU), and second-line 
irinotecan. Clinicians were unaware of BRAF-status 
 
Results 
231 patients (9.1%) had BRAF-mutant tumours. BRAF-mutation conferred 
significantly worse survival independent of associated clinicopathological 
factors known to be prognostic. Compared with wild-type, BRAF-mutant 
patients in COIN treated with first-line OxFU had similar DCR (59.2% vs 72%; 
adjusted OR=0.76,p=0.24) and PFS (5.7 vs 6.3 months; adjusted HR=1.14, 
p=0.26). Following progression on first-line chemotherapy, BRAF-mutant 
patients had a markedly shorter P-PS (4.2 vs 9.2 months, adjusted 
HR=1.69,p<0.001). BRAF-mutant status did not confer a disadvantage for 
patients without progression having planned chemotherapy-free intervals (OS 
adjusted HR=0.97, p=0.75). 
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Fewer BRAF-mutant patients received second-line treatment (33% vs 51%, 
p<0.001), but BRAF-mutation was not associated with inferior second-line 
outcomes (RR adjusted OR=0.56, p=0.45; PFS adjusted HR=1.01, p=0.93). 
 
Conclusions 
 
BRAF-mutant aCRC confers a markedly worse prognosis independent of 
associated clinicopathological features. Chemotherapy provides meaningful 
improvements in outcome throughout treatment lines. Post-progression 
survival is markedly worse and vigilance is required to ensure appropriate 
delivery of treatment after first-line progression. However, BRAF-mutant 
patients may still enjoy treatment breaks when not progressing. 
 
 
Key messages 
 
This is the largest study of BRAF-mutant aCRC. BRAF-mutant aCRC 
patients derive similar relative benefit from chemotherapy as wild-types; 
poor prognosis is not primarily due to chemoresistance. Instead, the point 
at which outcomes differ is following progression on first-line 
chemotherapy. BRAF-mutant aCRC patients can benefit from treatment 
breaks when stable, and from second-line chemotherapy. 
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INTRODUCTION 
 
The V600E activating mutation in  BRAF (BRAF-mutant) is found in the tumours 
of 8-12% patients with advanced colorectal cancer (aCRC). BRAF-mutant 
aCRC is consistently associated with poor overall survival (OS) and 
progression free survival (PFS) in case series[1,2,3] and randomised controlled 
trials (RCTs).[4,5] In a recent RCT of previously untreated aCRC, median OS 
was 13.4 months in BRAF-mutant patients compared with 37.1 months in RAS 
and BRAF wild-types.[6] There is urgent need to optimise treatment strategies 
to improve outcomes in this population. 
 
 BRAF-mutant aCRC is well studied: most previous work has described poor 
prognosis, clinical characterisation, or assessment of sub-group outcomes in 
RCTs with chemotherapy combined with anti-EGFR agents or bevacizumab. 
However many important clinical and biological questions remain. Firstly the 
mechanism for the poor prognosis is poorly understood, and it is unclear at 
what point in the aCRC treatment pathway that BRAF-mutant outcomes diverge 
from wild-types; whilst OS is uniformly poor, less impact is seen with PFS 
compared with wild-types.[7,8,] It has been hypothesised that poor outcomes are 
secondary to intrinisc chemoresistance but there is a paucity of data describing 
the outcomes of BRAF-mutant aCRC with chemotherapy alone, particularly 
beyond the first-line. 
 
Importantly previous publications have not performed careful multivariate 
analysis. This is critical as BRAF-mutant aCRC is associated with 
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clinicopathological features which are themselves negative prognostic 
factors,[9] including defective mismatch repair (dMMR) status[7,10], right sided 
primary tumour location (PTL)[11] and a high incidence of peritoneal 
metastases.[12] The observed poor outcomes may instead be driven by such 
factors so it is essential to prospectively factor this into analyses of outcomes. 
Only one study has adjusted BRAF outcomes by one of these factors, dMMR, 
and found poor outcomes to be independent of this.[7]  
 
Detailed analysis of the natural history of BRAF-mutant aCRC will provide more 
clarity to patients and their physicians about prognosis and an evidence base 
to quantitate the benefits of different chemotherapy strategies throughout the 
treatment pathway. Ultimately this will help in devising strategies to maximise 
their outcomes.  
 
Maximising outcomes with chemotherapy are particularly important in this 
aCRC sub-group, as the addition of other agents used in aCRC  and trials of 
novel agents have been disappointing. BRAF-mutant status as a negative 
predictive marker for anti-EGFR agents has been controversial.[5,12] However, 
a recent meta-analysis comparing outcomes of BRAF-mutant patients in RCTs 
treated with anti-EGFR agents plus chemotherapy or chemotherapy alone 
reported an OS hazard ratio of 0.97, making it difficult to justify the added 
toxicity and cost.[14] Additionally the use of targeted agents to improve outcomes 
in BRAF-mutant aCRC have been disappointing, in contrast to succeses in 
melanoma.[15] Combined BRAF and MEK inhibition in a heavily pretreated 
BRAF-mut aCRC population, produced a median PFS was 3.5 months,[16] 
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contrasting with 9.4 months with the same combination in BRAF-mutant 
melanoma.[15] One promising strategy for this patient group is triplet 
chemotherapy plus bevacizumab,[6] but many patients will not be fit enough for 
this regimen. Thus, analysis of outcomes on doublet and singlet chemotherapy 
remains highly relevant. 
 
We have examined individual patient data from three RCTs to identify points on 
the treatment pathway at which BRAF-mutant outcomes differ from BRAF wild-
type patients treated with cytotoxic chemotherapy, to assess the impact of 
potential confounders and to provide clinicians with detailed information of 
outcomes with various chemotherapy strategies. We analysed treatment 
outcomes in two first-line RCTs with oxaliplatin/fluorouracil (OxFU), behaviour 
during chemotherapy-free intervals and following disease progression. We then 
report patterns of, and outcomes with second-line therapy. In order to avoid 
potential interactions of BRAF status with anti-EGFR drugs we focus on 
patients treated in arms that did not include targeted therapies. Potential 
confounding factors were prospectively identified, and analyses adjusted 
accordingly. BRAF-status was unknown to clinicians treating patients in each 
trial, eliminating potential bias. 
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PATIENTS AND METHODS: 
 
Patient population and treatment: 
 
Individual patient data were obtained from selected arms of three large 
randomised trials, to reflect different clinical uses of standard cytotoxic 
chemotherapy (without targeted therapy) in aCRC (Figure 1).  
 FOCUS (ISRCTN 79877428) was a sequencing trial of first-line and 
planned second-line therapy, and provided a cohort of 430 patients 
receiving single-agent 5FU ahead of planned second-line irinotecan or 
oxaliplatin-based therapy, plus a cohort of 357 randomised to first-line 
doublet (IrFU or OxFU).[17] 
 COIN (ISRCTN 27286448) provided a cohort of 1284 patients 
randomised to first-line oxaliplatin/fluoropyrimidine (OxFp) doublet 
either continuously (Arm A) or with planned chemotherapy-free 
intervals (Arm C).[18,19] 
 PICCOLO (ISRCTN 93248876) provided a cohort of 511 OxFp-
resistant patients treated with second-line irinotecan.[12,20]  
Inclusion criteria for FOCUS and COIN were consistent and both patient 
groups were treated in centres in the UK. Full reports of these studies have 
been published.[12,17-20] National ethical approval and patient consent was 
obtained for all aspects of the clinical and translational research. DNA 
extraction and genotyping for mutations including BRAFV600E was performed 
retrospectively as previously reported.[12,21,22] 
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Statistical analysis 
 
Stata was used (Release 12 (2011), StataCorp. College Station, Texas). 
Baseline patient characteristics were compared between BRAF-mutant 
patients (with or without other MEK/AKT pathway mutations) and BRAF wild-
type patients using two-tailed T-tests, Wilcoxon rank sum tests (for variables 
with non-normally distributed frequency distributions) and Pearson Chi-
squared tests (for categorical variables). 
 
In addition to OS (time from randomisation to death from any cause), three 
treatment-related clinical endpoints were used: PFS (time from randomisation 
to first evidence of progression or death); 12-week RECIST response rate 
(RR), and disease control rate (DCR).[23] Finally, we compared post-
progression survival time (P-PS), defined as time from progression to death in 
those with a progression event, however when date of progression data was 
unavailable date of last chemotherapy cycle was used instead.   
 
The prognostic influence of BRAF-mutant status on survival outcomes (PFS, 
P-PS and OS) for first-line trials (FOCUS and COIN), then the second-line trial 
(PICCOLO) were analysed using Cox proportional hazards modelling and 
described using hazard ratios (HRs) and 95% confidence intervals (CIs), 
adjusted for factors known to be prognostic or likely to interact with BRAF-
status.  In COIN and FOCUS these were: WHO performance status (2 vs 0/1); 
primary tumour resected (yes vs no); PTL (right colon vs other); platelet count 
(< vs ≥ 400,000/μl); peritoneal metastases (present vs absent) and mismatch 
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repair (MMR) status. In PICCOLO, adjustment was made for: response to 
previous therapy; performance status; peritoneal metastases; primary tumour 
resected and PTL. As these factors individually interact with prognosis, 
adjusted values are reported primarily but unadjusted values are provided. 
 
Kaplan-Meier (KM) curves were plotted. For response endpoints, odds ratios 
(ORs) and 95% CIs were estimated from logistic regression models for the 
effect of BRAF-mutant status, adjusted for the markers previously described. 
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RESULTS 
 
Clinicopathological variables associated with BRAF-mutant aCRC  
BRAF status was available for 787/2135 (36.9%) patients in FOCUS, 
1284/1630 (78.8%) in COIN and 459/511 (89.8%) in PICCOLO (Figure 1). 
The BRAF-mutant prevalence was consistent with published values (FOCUS 
61/787 [7.8%], COIN 130/1284 [10.1%], PICCOLO 40/459 [8.7%]). BRAF-
mutant patients were more likely than BRAF wild-type to be female, have 
right-sided PTL, have peritoneal metastases and nodal metastases, but less 
likely to have lung metastases. BRAF-mutant tumours were more likely to 
have dMMR than BRAF wild-type tumours (12.6% vs 3.0%, p<0.001). 8/2530 
(0.3%) patients’ tumours had dual mutations in both BRAF and KRAS (Table 
1) 
 
 BRAF-status as a prognostic marker for overall survival 
 
BRAF-mutant status was a significant prognostic marker for OS in both first-
line studies (COIN 9.8 vs 16.6 months, unadjusted HR =1.78 [1.46-2.17], 
p<0.001; FOCUS 10.9 vs 16.2 months, unadjusted HR=1.55 [1.18-2.04], 
p=0.030)(Table 2). Combining these data [n=2071] gave a median OS of 10.8 
vs 16.4 months (HR=1.49 [1.23-1.80] p<0.001)(Figure 2). 
 
As BRAF-mutant status was associated with clinicopathological 
characteristics that may interact with survival (Table 1), their prognostic 
impact was explored in a univariate, then multivariate analysis in data pooled 
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from the first-line trials. Significant factors predicting poor OS on univariate 
testing were BRAF-mutant status, poor performance status, high platelet 
count, right PTL, peritoneal metastases, primary tumour in-situ and dMMR 
status; in multivariate testing, all factors remained significant other than 
dMMR status (Supplementary Table 1). 
 
Following adjustment, BRAF-mutant status remained a significant prognostic 
marker in both trials (COIN adjusted HR =1.51 [1.19-1.91], p<0.001; FOCUS 
adjusted HR=1.44 [1.04-2.00], p=0.030)(Table 2). Given the demonstrated 
prognostic effect of clinicopathological factors associated with BRAF-mutant 
status all subsequent analyses are adjusted. 
 
Impact of BRAF-status on treatment-related endpoints on first-line 
combination chemotherapy 
 
In contrast to its marked effect on OS, BRAF-mutant status had modest or 
insignificant impact on the first-line PFS and response endpoints. Although, 
patients treated with first-line OxFP in COIN, BRAF-mutant patients had an 
inferior 12-week RR (34.3% vs 47.5%, adjusted OR=0.58 [0.37-0.92], 
p=0.020), the differences in DCR and PFS were not significant (DCR 59.2% 
vs 72.0%, adjusted OR=0.76 [0.49-1.20], p=0.24; PFS 5.7 vs. 6.3 months, 
adjusted HR=1.14 [0.91-1.42], p=0.26)(Table 2). There was no evidence of a 
differential effect of BRAF status according to the doublet used (OxFU or 
OxCap)(data not shown).  
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Similarly for patients treated with first-line combination chemotherapy in 
FOCUS, there were no differences in efficacy endpoints in BRAF-mutant 
compared with BRAF wild-type patients: PFS was 8.2 vs 8.8 months (adjusted 
HR=1.07 [0.69-1.67], p=0.75); RR was 43.7% vs 43.1% (adjusted OR=1.09 
[0.45-2.65], p=0.85); DCR was 68.9% vs 69.9% (adjusted OR=1.01 [0.36-
2.84], p=0.97)(Table 2). There was no evidence of a differential effect of 
BRAF-status according to regimen used (OxFU or IrFU, p=0.26).  
 
Impact of BRAF-status on post-progression survival 
 
Following progression on first-line combination chemotherapy, BRAF-mutant 
patients had markedly reduced P-PS compared with BRAF-wt in both first-line 
trials. In COIN PPS was 3.2 months in BRAF-mutant compared with 8.6 
months in BRAF-wt patients (adjusted HR=1.72 [1.35-2.19], p<0.001). 
Similarly in FOCUS inferior P-PS was observed between BRAF-mutant and 
wild-types (3.2 vs 8.1 months; adjusted HR=1.65 [1.03-2.67], p=0.038)(Table 
2). Combining this data P-PS was inferior in the BRAF-mutant compared with 
the BRAF-wt group (3.2 vs 8.6 months, HR=1.72 [1.35-2.19], p<0.001)(Figure 
3).  These marked differences were independent of first-line treatment 
received (in COIN, OxFU vs OxCap p=0.53, in FOCUS OxFU vs IrFU 
p=0.91)(data not shown).  
 
When other prognostic factors were tested in a combined multivariate model, 
a significant negative effect on P-PS was seen after first-line chemotherapy 
for peritoneal metastases and dMMR status (peritoneal metastases HR=1.39, 
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p<0.0001; dMMR HR=1.38, p=0.025). However the negative prognostic 
impact of peritoneal metastases and dMMR appears limited to the BRAF wild-
type population, and neither factor impacted further on the poor P-PS seen in 
BRAF-mutant patients (interaction p= 0.005 and p=0.05 respectively), 
showing that it is the BRAF-mutation driving the observed poor outcomes 
(Supplementary Table 2). 
 
Impact of BRAF status on salvage therapy 
 
To explore the mechanism for inferior first-line P-PS in BRAF-mutant patients, 
we studied uptake of post-progression therapies and survival outcomes of 
those who received second-line treatment, compared to those who did not. 
 
In COIN, BRAF-mutant patients were less likely to receive second-line 
therapy after first-line progression (33% vs. 51%, p=0.0002). Similarly, after 
completion of the FOCUS plan, which for all patients included two drugs (FU 
and either oxaliplatin or irinotecan, given over 1 or 2 lines), 123/401 (30.7%) 
BRAF wild-type and 3/29 (10.3%) BRAF-mutant patients received subsequent 
salvage therapy (p=0.020)(data not shown).   
 
The duration of second-line therapy (regimens including FU-based, Ir-based, 
oxaliplatin-based, cetuximab and bevacizumab) for those who received it, was 
unaffected by BRAF-mutant status (COIN p=0.55, FOCUS p=0.18). The only 
exception was the subgroup of FOCUS patients randomised to receive IrFU 
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after progression on FU alone, where BRAF-mutant status was associated 
with shorter treatment duration (p=0.019)(data not shown).  
 
OS was improved in COIN for those who received subsequent second-line 
chemotherapy compared with those without, regardless of BRAF-status 
(BRAF-mut 16.1 vs 7.8 months [HR=0.56, p=0.005]; BRAF wild-type 21.1 vs 
11.6 months [HR=0.48, p<0.001]; interaction p=0.66)(Figure 4). However 
BRAF-mutant patients had worse OS whether treated with second-line 
chemotherapy, (HR=1.91[1.36-2.69], p<0.001), or not (HR=1.44 [1.12-1.84], 
p=0.004), compared with wild-types. 
 
Impact of chemotherapy-free intervals in BRAF-mutant patients  
 
In contrast to the worse outcome after failure of first-line chemotherapy, there 
was no evidence that BRAF-mutant patients fare less well with a planned 
treatment break when first-line treatment has not yet failed. COIN, which 
compared continuous or intermittent chemotherapy strategies, found that 
intermittent chemotherapy in the entire population was non-inferior for OS 
(adjusted HR=1.04 [0.98–1.10], p=0.16).[19] In BRAF-mutant patients this was 
also the case (adjusted HR=0.97 [0.80–1.17], p=0.75) (Figure 4). 
 
In all patients progression events in patients during chemotherapy breaks led 
to shorter PFS (adjusted HR=1.27 [1.21–1.33], p<0.001).[19] Interestingly, 
however, BRAF-mutant patients were the only molecular sub-group not to have 
a PFS disadvantage with intermittent chemotherapy (BRAF-mutant PFS 
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adjusted HR=1.09 [0.91–1.31], p=0.33; BRAF-wt PFS adjusted HR=1.29 [1.21–
1.37], p<0.001; interaction p=0.14)(Figure 4).   
 
Outcomes with single agent chemotherapy 
 
We also examined the impact of BRAF-status on outcomes with single agent 
chemotherapy. With first-line single agent 5FU (n=430), PFS was similar in 
BRAF-mutant and BRAF-wt patients (6.5 vs 6.7 months; adjusted HR=0.96 
[0.60-1.52], p=0.30); RR was 17.2% vs 21.7% (adjusted OR=0.54 [0.17,1.72], 
p=0.30); DCR 48.3% vs 60.6% (adjusted OR=0.72 [0.27-1.94], 
p=0.52)(Supplementary Table 3). Following progression on single agent 5FU, 
PPS was reduced in the BRAF-mutant group (3.5 vs 9.3 months; adjusted HR 
= 2.19[1.30-3.69],p=0.003)(Supplementary Table 3), again with a lower 
uptake of second-line therapies (39.3% vs 58.4%, p=0.048). 
 
The impact of BRAF-status on outcomes for the 459 patients treated with 
second-line irinotecan was examined in the PICCOLO trial. Whilst OS was 
shorter for BRAF-mutant patients compared with BRAF wild-type, the 
difference did not reach statistical significance: 6.7 vs 10.2 months (adjusted 
HR=1.21 [0.84-1.76], p=0.31)(Supplementary Table 3 and Supplementary 
Figure 1). Similar to first-line data efficacy data and subsequent outcomes 
with salvage therapy, there were no significant differences between BRAF-
mutant to BRAF wild-type patients in PFS (3.5 vs 4.0 months, adjusted 
HR=1.01 [0.69-1.49], p=0.93), RR (5.0% vs. 8.1%, adjusted OR=0.56 [0.13-
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2.49], p=0.45)) and DCR (42.5% vs. 47.7% (adjusted OR=0.82[0.41-1.62], 
p=0.57)(Supplementary Table 3). 
 
BRAF-mutant patients treated with anti-EGFR agents 
 
The benefit of the addition of anti-EGFR agents to chemotherapy in COIN and 
PICCOLO has been previously reported. In COIN, whilst in PICCOLO BRAF-
mut patients treated with IrPan had significantly shorter OS than those treated 
with Ir alone (interaction p=0.029). Whilst a less clear relationship was seen 
for PFS (IrPan vs Ir HR = 1.40, 0.82-2.39), but with negative interaction test 
there was a significant worsening of P-PS for patients treated with 
panitumumab who had mutation, compared with Ir alone. For these reasons 
we did not include this population in the primary analysis. 
 
BRAF-mut treated with anti-EGFR agents had consistently inferior outcomes 
than RAS-wt patients in both trials. Within COIN BRAF-mut had inferior OS 
(7.2 vs 19.9 mths, HR=2.96[1.93-4.53], p<0.001), PFS (4.8 vs 9.3mths, 
HR=1.84[1.23-2.75], p=0.003), and markedly worse P-PS (1.9 vs 9.7 mths, 
HR=3.12 [2.14-4.54]). Similarly in PICCOLO (n=321) BRAF-mut patients had 
inferior OS (4.4 vs 11.1mths, HR=2.31[1.61-3.33],p<0.001), PFS (2.7 vs 5.5 
mths, HR=1.70[1.24-2.61], p=0.002) and P-PS (3.2 vs 6.0 mths, 
HR=1.83[1.24-2.61], p=0.002). 
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DISCUSSION 
 
This is the largest and most comprehensive clinical series assessing the 
outcomes of BRAF-mutant patients treated with chemotherapy at different 
points of the aCRC pathway. The poor outcomes of advanced BRAF-mutant 
aCRC are well described, but these cancers are associated with specific 
clinicopathological features: older age, right-sided primary tumour, high grade, 
deficient MMR, mucinous histology and peritoneal and lymph node 
metastases,[7,9-12] most of which interact with prognosis. In a careful 
multivariate analysis in a large, prospectively gathered cohort, BRAF-mutation 
still conferred a worse prognosis and is not simply attributable to associated 
clinic-pathological features.  
 
A novel and striking finding is that this poor outlook is not driven by primary 
chemo-resistance, and that the point at which outcomes markedly diverge 
from wild-types is following progression on first-line chemotherapy. We 
observed no difference in the adjusted PFS between BRAF-mutant and wild-
type patients receiving first-line chemotherapy or with second-line irinotecan 
monotherapy in our second-line trial. Similarly, we found no difference in the 
relative benefit of second-line therapy after failure of first-line chemotherapy. 
Results were consistent between both first-line trials, independent of 
chemotherapy strategy and other standard prognostic factors.  
 
The combination of oxaliplatin and a fluoropyrimidine is a commonly used 
first-line therapy in aCRC. Other groups have shown that PFS on first-line 
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fluoropyrimidine is equivalent in BRAF-mutant and wild-type patients.[9]  
Furthermore, oxaliplatin may be particularly important in BRAF-mutant 
patients. Biomarker analysis from MOSAIC (testing the addition of oxaliplatin 
to FP in adjuvant treatment of early CRC) reported that the OS HR for OxFP 
vs FP alone was 0.55 in the BRAF-mutants, and 0.93 in wild-types.[24] The 3 
year disease-free survival, 5 year OS and 10 year OS absolute differences for 
the addition of oxaliplatin were 16.4%, 9.5% and 10.1% respectively in BRAF-
mut patients, compared with only 2.4%, 1% and 1.9% in wild-types.[24] In the 
TRIBE study (FOLFOXIRI plus bevacizumab vs FOLFIRI plus bevacizumab in 
the first-line treatment of aCRC), PFS HR for the addition of oxaliplatin to 
FOLFIRI/Bevacizumab in BRAF-mutant patients was 0.54, compared with 
0.85 in RAS/RAF wild-types; the ORs for response was 1.82 and 1.17 
respectively.[6] Biomarker analysis from the FOCUS trial, comparing first-line 
OxFU with FU alone produced HRs of 0.43 for PFS and 0.54 for OS in BRAF-
mutant patients, compared with 0.68 and 0.86 respectively in BRAF wild-
types.[21]  
 
BRAF-mutant patients have markedly worse survival after progression on 
first-line treatment, with important implications for patient management. 
Second-line therapy provides equivalent relative benefits to wild-type patients 
and fewer BRAF-mutant patients receive second line therapy. It is important 
to emphasise that treating physicians were unaware of BRAF-status, so this 
finding is not due to selection bias. We therefore advocate extra vigilance 
when treating BRAF-mutant patients, to detect progression and rapidly 
institute second-line therapy, in the knowledge that this has the capacity to 
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significantly improve survival. One potential response to the observed rapid 
decline after first-line progression in BRAF-mutant patients would be to 
upgrade first-line therapy to a FOLFOXIRI-based regimen. However, only a 
subset of patients is fit enough to receive these more intensive treatments, 
instead many patients are routinely treated with doublets.  
 
Equally importantly for routine practice, we found that whilst BRAF-mutant 
patients are at risk of accelerated decline after progression, this does not 
mean that they cannot safely enjoy an intermittent strategy including periods 
off chemotherapy when treatment has not yet failed. Thus such patients with 
disease control can be appropriately counselled about the safety of 
chemotherapy free intervals.  
 
These data allow the development of two non-mutually exclusive hypotheses 
to explain the inferior survival of BRAF-mutant patients. Firstly these patients 
may simply have a worse prognosis from initiation of their treatment 
programme and their equivalent PFS and DCR reflects enhanced relative 
benefit from first-line chemotherapy, particularly with oxaliplatin, in 
comparison with wild-type patients. Alternatively the poor survival may be 
driven by mechanisms mediating first-line chemotherapy resistance when 
superimposed on the BRAF-mutational landscape. This is supported by 
markedly worse post-progression survival independent of the delivery of 
second-line treatment, and the lack of PFS and OS deterioration in BRAF-
mutant patients stable on first-line Ox/FP receiving chemotherapy-free breaks.  
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Disappointing results of BRAF-inhibitors as single agents in aCRC[25] and a 
growing appreciation of the molecular complexity of BRAF-mut aCRC[26] 
suggest that targeted approaches may require multi-agent combinations. Early 
clinical studies report encouraging clinical activity and acceptable toxicity with 
the combination of a BRAF-inhibitor, a MEK inhibitor and an anti-EGFR 
agent.[27] These regimens are complex and likely to be expensive and will 
complement rather than replace chemotherapy.  
 
This, the largest and most comprehensive analysis of chemotherapy 
outcomes in BRAF-mutant CRC patients provides new and important 
information with clinical relevance. In summary, BRAF-mutation confers a 
markedly worse prognosis independent of associated clinicopathological 
features. However chemotherapy does provide meaningful improvements in 
outcome throughout treatment lines. Post-progression survival is markedly 
worse and vigilance is required to ensure the appropriate delivery of treatment 
after first-line progression. 
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Legend to Figures 
 
Figure 1- Consort diagram of study participants from the FOCUS, COIN and 
PICCOLO trials 
 
Figure 2 –OS KM curves for BRAF-mut vs BRAF-wt for first line 
chemotherapy (FOCUS and COIN, all strategies) 
 
Figure 3 - Post-progression survival KM curves for BRAF-mut vs BRAF-wt 
following failure on first-line chemotherapy (COIN and FOCUS) 
 
Figure 4 – Forest plot of OS and PFS for first-line intermittent vs continuous 
chemotherapy by BRAF-status
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